Galapagos Genomics NV is a biotech company located in Mechelen, Belgium. The company was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. The company has its own internal discovery programs which it combines with drug discovery and pre-clinical service activities for other biotech and pharmaceutical companies. Onno van de Stolpe is the CEO of the company.

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.

References

• Edwards PJ., The impact of parallel chemistry in drug discovery, IDrugs. 2006 May;9(5):347-53.

See also

• FlandersBio

Source

• Galapagos Genomics gaat zelf medicijnen ontwikkelen (Dutch)
• Een rotsvast geloof in de Vlaamse biotech